Characterization and spinal fusion effect of rabbit mesenchymal stem cells

BMC Research Notes

Tao-Chen Lee²  Dar-Jen Hsieh¹  Tsung-Ming Su³  Pei-Wen Chang Chien³  Wan-Ching Lin⁴  Nyuk-Kong Chang⁴  Yu-Hua Huang³  Tsung-Han Lee³ 

[1] Sunmax Biotechnology CO., LTD., Tainan, Taiwan;Department of Neurosurgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan;Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital and Chang, Gung University College of Medicine, Kaohsiung, Taiwan;Department of Center for Laboratory Animals, Kaohsiung Chang Gung Memorial, Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

关键词: Mesenchymal stem cell;    Spinal fusion;    Characterization;   

Others  :  1140499
DOI  :  10.1186/1756-0500-6-528

 received in 2013-05-29, accepted in 2013-12-03,  发布年份 2013

【 摘 要 】

Background

The surface markers of mesenchymal stem cells (MSCs) of rabbits have been reported only sporadically. However, interest in the spinal fusion effect of MSCs has risen recently. The purpose of this research was to study the surface markers and spinal fusion effect of rabbit MSCs.

Results

Of our rabbit MSCs, 2% expressed CD14, CD29, and CD45, 1% expressed CD90 and 97% expressed CD44. These results implied the MSCs were negative for CD14, CD29, CD45, and CD90, but positive for CD44. The surgical results showed that satisfactory fusion occurred in 10 rabbits (83%) in the study group and unsatisfactory fusion in 2 (17%). In the control group, satisfactory fusion was found in 3 rabbits (25%) and unsatisfactory fusion in 9 (75%). Statistical analysis showed the study group had significantly better spinal fusion results than the control group.

Conclusions

The surface markers of human and rabbit MSCs are not exactly the same. Rabbit MSCs do not have positive reactivity for CD29 and CD90, which are invariably present on human MSCs. The allogeneic undifferentiated rabbit MSCs were able to promote spinal fusion and did not induce an adverse immune response.

【 授权许可】

   
2013 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
• [2]Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
• [3]Deans RJ, Moseley AB: Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000, 28:875-884.
• [4]Bianco P, Gehron Robey P: Marrow stromal stem cells. J Clin Invest 2000, 105:1663-1668.
• [5]Karaoz E, Aksoy A, Ayhan S, Sariboyaci AE, Kaymaz F, Kasap M: Characterization of mesenchymal stem cells from rat bone marrow: ultrastructural properties, differentiation potential and immunophenotypic markers. Histochem Cell Biol 2009, 132:533-546.
• [6]Lapi S, Nocchi F, Lamanna R, Passeri S, Iorio M, Paolicchi A, Urciuoli P, Coli A, Abramo F, Miragliotta V, Giannessi E, Stornelli MR, Vanacore R, Stampacchia G, Pisani G, Borghetti L, Scatena F: Different media and supplements modulate the clonogenic and expansion properties of rabbit bone marrow mesenchymal stem cells. BMC Res Notes 2008, 1:53. BioMed Central Full Text
• [7]Martínez-Lorenzo MJ, Royo-Cañas M, Alegre-Aguarón E, Desportes P, Castiella T, García-Alvarez F, Larrad L: Phenotype and chondrogenic differentiation of mesenchymal cells from adipose tissue of different species. J Orthop Res 2009, 27:1499-1507.
• [8]Nakajima T, Iizuka H, Tsutsumi S, Kayakabe M, Takagishi K: Evaluation of posterolateral spinal fusion using mesenchymal stem cells: differences with or without osteogenic differentiation. Spine (Phila Pa 1976) 2007, 32:2432-2436.
• [9]Bosnakovski D, Mizuno M, Kim G, Ishiguro T, Okumura M, Iwanaga T, Kadosawa T, Fujinaga T: Chondrogenic differentiation of bovine bone marrow mesenchymal stem cells in pellet cultural system. Exp Hematol 2004, 32:502-509.
• [10]Lee TC, Ho JT, Hung KS, Chen WF, Chung YH, Yang YL: Bone morphogenetic protein gene therapy using a fibrin scaffold for a rabbit spinal-fusion experiment. Neurosurgery 2006, 58:373-380.
• [11]Lee TC, Wang CJ, Yang YL, Huang YH, Lin WC, Chang SY: Bone morphogenetic protein-2 expression in spinal fusion masses enhanced by extracorporeal shock wave treatment: a rabbit experiment. Acta Neurochir (Wien) 2010, 152:1779-1784.
• [12]Lee TC, Yang YL, Chang NK, Lin TS, Lin WC, Liu YS, Wang CJ: Biomechanical testing of spinal fusion segments enhanced by extracorporeal shock wave treatment in rabbits. Chang Gung Med J 2009, 32:276-282.
• [13]Boden SD, Schimandle JH, Hutton WC: An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine (Phila Pa 1976) 1995, 20:412-420.
• [14]Blanco JF, Graciani IF, Sanchez-Guijo FM, Muntión S, Hernandez-Campo P, Santamaria C, Carrancio S, Barbado MV, Cruz G, Gutierrez-Cosío S, Herrero C, San Miguel JF, Briñon JG, del Cañizo MC: Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: comparison with bone marrow mesenchymal stromal cells from the same subjects. Spine (Phila Pa 1976) 2010, 35:2259-2265.
• [15]Stich S, Loch A, Leinhase I, Neumann K, Kaps C, Sittinger M, Ringe J: Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur J Cell Biol 2008, 87:365-376.
• [16]Bruder SP, Kraus KH, Goldberg VM, Kadiyala S: The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998, 80:985-996.
• [17]Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, Smith A, Kadiyala S: Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 2003, 85-A:1927-1935.
• [18]Kuo YR, Goto S, Shih HS, Wang FS, Lin CC, Wang CT, Huang EY, Chen CL, Wei FC, Zheng XX, Lee WP: Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009, 87:1769-1777.
• [19]Minamide A, Yoshida M, Kawakami M, Yamasaki S, Kojima H, Hashizume H, Boden SD: The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion. Spine (Phila Pa 1976) 2005, 30:1134-1138.
• [20]Cinotti G, Patti AM, Vulcano A, Della Rocca C, Polveroni G, Giannicola G, Postacchini F: Experimental posterolateral spinal fusion with porous ceramics and mesenchymal stem cells. J Bone Joint Surg Br 2004, 86:135-142.
• [21]Undale A, Fraser D, Hefferan T, Kopher RA, Herrick J, Evans GL, Li X, Kakar S, Hayes M, Atkinson E, Yaszemski MJ, Kaufman DS, Westendorf JJ, Khosla S: Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. J Orthop Res 2011, 29:1804-1811.
• [22]Young RG, Butler DL, Weber W, Caplan AI, Gordon SL, Fink DJ: Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 1998, 16:406-413.
• [23]Goldschlager T, Rosenfeld JV, Ghosh P, Itescu S, Blecher C, McLean C, Jenkin G: Cervical interbody fusion is enhanced by allogeneic mesenchymal precursor cells in an ovine model. Spine (Phila Pa 1976) 2011, 36:615-623.